Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;9(4):406-13.
doi: 10.1161/CIRCOUTCOMES.115.002043. Epub 2016 May 31.

Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program

Geoffrey D Barnes  1 , Maggie A Stanislawski  2 , Wenhui Liu  2 , Anna E Barón  2 , Ehrin J Armstrong  2 , P Michael Ho  2 , Andrew Klein  2 , Thomas M Maddox  2 , Brahmajee K Nallamothu  2 , John S Rumsfeld  2 , Thomas T Tsai  2 , Steven M Bradley  2
Affiliations

Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program

Geoffrey D Barnes et al. Circ Cardiovasc Qual Outcomes. 2016 Jul.

Abstract

Background: Several antiplatelet medications used during and after percutaneous coronary intervention (PCI) are contraindicated for specific patient groups. A broad assessment of contraindicated medication use and associated clinical outcomes is not well described.

Methods and results: Using national Veterans Affairs Clinical Assessment, Reporting, and Tracking Program data for all PCI between 2007 and 2013, we evaluated patients with contraindications to commonly used antiplatelet medications during and after PCI, defined in accordance with package inserts. Adjusted association between contraindicated medication use and outcomes of periprocedural bleeding and 30-day mortality were assessed using Cox proportional hazards with inverse probability weighting. Among 64 294 patients undergoing PCI, 11 315(17.6%) had a contraindication to a common antiplatelet medication and 737 (6.5%) of these patients received a contraindicated medication. In unadjusted analyses, any contraindicated medication use was associated with both increased bleeding and 30-day mortality. In adjusted models, contraindicated abciximab use in patients with thrombocytopenia (hazard ratio, 2.23; 95% confidence interval, 1.58-3.16) and in patients with a previous stroke (hazard ratio, 1.93; 95% confidence interval, 1.37-2.71) remained significantly associated with increased bleeding. Contraindicated abciximab use was not significantly associated with 30-day mortality in adjusted models. Use of eptifibatide in dialysis patients was not significantly associated with an increased risk of bleeding or mortality.

Conclusions: In this national cohort, ≈18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications.

Keywords: abciximab; eptifibatide; medication errors; mortality; percutaneous coronary intervention.

PubMed Disclaimer

Figures

Figure
Figure
Hazard Ratios for Peri-Procedural Bleeding and 30 Day Mortality with Contraindicated Medication Use
See this image and copyright information in PMC

References

    1. IOM . Preventing Medication Errors: Quality Chasm Series. 2007.
    1. Milani RV, Oleck SA, Lavie CJ. Medication errors in patients with severe chronic kidney disease and acute coronary syndrome: the impact of computer-assisted decision support. Mayo Clin Proc. 2011;86:1161–1164. - PMC - PubMed
    1. Tsai TT, Maddox TM, Roe MT, Dai D, Alexander KP, Ho PM, Messenger JC, Nallamothu BK, Peterson ED, Rumsfeld JS. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302:2458–2464. - PubMed
    1. Sandhu A, Seth M, Dixon S, Share D, Wohns D, Lalonde T, Moscucci M, Riba AL, Grossman M, Gurm HS. Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes. 2013;6:293–298. - PubMed
    1. Hira RS, Kennedy K, Jneid H, Alam M, Basra SS, Petersen LA, Ballantyne CM, Nambi V, Chan PS, Virani SS. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;63:2876–2877. - PubMed

MeSH terms